238 related articles for article (PubMed ID: 16280056)
1. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis.
Reis-Filho JS; Milanezi F; Carvalho S; Simpson PT; Steele D; Savage K; Lambros MB; Pereira EM; Nesland JM; Lakhani SR; Schmitt FC
Breast Cancer Res; 2005; 7(6):R1028-35. PubMed ID: 16280056
[TBL] [Abstract][Full Text] [Related]
2. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy.
Gilbert JA; Goetz MP; Reynolds CA; Ingle JN; Giordano KF; Suman VJ; Blair HE; Jenkins RB; Lingle WL; Reinholz MM; Adjei AA; Ames MM
Mol Cancer Ther; 2008 Apr; 7(4):944-51. PubMed ID: 18413808
[TBL] [Abstract][Full Text] [Related]
3. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas.
Reis-Filho JS; Pinheiro C; Lambros MB; Milanezi F; Carvalho S; Savage K; Simpson PT; Jones C; Swift S; Mackay A; Reis RM; Hornick JL; Pereira EM; Baltazar F; Fletcher CD; Ashworth A; Lakhani SR; Schmitt FC
J Pathol; 2006 Aug; 209(4):445-53. PubMed ID: 16739104
[TBL] [Abstract][Full Text] [Related]
4. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.
Bhargava R; Gerald WL; Li AR; Pan Q; Lal P; Ladanyi M; Chen B
Mod Pathol; 2005 Aug; 18(8):1027-33. PubMed ID: 15920544
[TBL] [Abstract][Full Text] [Related]
5. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
6. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
[TBL] [Abstract][Full Text] [Related]
7. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
[TBL] [Abstract][Full Text] [Related]
8. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas.
Nunes CB; Rocha RM; Reis-Filho JS; Lambros MB; Rocha GF; Sanches FS; Oliveira FN; Gobbi H
J Clin Pathol; 2008 Aug; 61(8):934-8. PubMed ID: 18474540
[TBL] [Abstract][Full Text] [Related]
11. Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas.
Gouvêa AP; Milanezi F; Olson SJ; Leitao D; Schmitt FC; Gobbi H
Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):103-8. PubMed ID: 16540740
[TBL] [Abstract][Full Text] [Related]
12. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.
Ricardo SA; Milanezi F; Carvalho ST; Leitão DR; Schmitt FC
J Clin Pathol; 2007 Sep; 60(9):1001-5. PubMed ID: 17158643
[TBL] [Abstract][Full Text] [Related]
13. Which breast carcinomas need HER-2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c-erbB2 protein domains.
Sapino A; Coccorullo Z; Cassoni P; Ghisolfi G; Gugliotta P; Bongiovanni M; Arisio R; Crafa P; Bussolati G
Histopathology; 2003 Oct; 43(4):354-62. PubMed ID: 14511254
[TBL] [Abstract][Full Text] [Related]
14. Gene amplification and immunohistochemical expression of ERBB2 and EGFR in cervical carcinogenesis. Correlation with cell-cycle markers and HPV presence.
Conesa-Zamora P; Torres-Moreno D; Isaac MA; Pérez-Guillermo M
Exp Mol Pathol; 2013 Oct; 95(2):151-5. PubMed ID: 23827764
[TBL] [Abstract][Full Text] [Related]
15. Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.
Kawamoto T; Ishige K; Thomas M; Yamashita-Kashima Y; Shu S; Ishikura N; Ariizumi S; Yamamoto M; Kurosaki K; Shoda J
J Gastroenterol; 2015 Apr; 50(4):467-79. PubMed ID: 25112701
[TBL] [Abstract][Full Text] [Related]
16. Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated-type breast carcinomas with 'stem-cell-like' features.
Tsuda H; Tani Y; Weisenberger J; Kitada S; Hasegawa T; Murata T; Tamai S; Hirohashi S; Matsubara O; Natori T
Cancer Sci; 2005 Jun; 96(6):333-9. PubMed ID: 15958055
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
[TBL] [Abstract][Full Text] [Related]
18. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies.
Hirsch FR; Scagliotti GV; Langer CJ; Varella-Garcia M; Franklin WA
Lung Cancer; 2003 Aug; 41 Suppl 1():S29-42. PubMed ID: 12867060
[TBL] [Abstract][Full Text] [Related]
20. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis.
Reis-Filho JS; Savage K; Lambros MB; James M; Steele D; Jones RL; Dowsett M
Mod Pathol; 2006 Jul; 19(7):999-1009. PubMed ID: 16648863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
